LONDON (ShareCast) - (ShareCast News) - Pharmaceutical company Shire (Xetra: S7E.DE - news) is reportedly mulling options to sweeten its multi-billion dollar, all-stock offer for US biotechnology group Baxalta (Berlin: 9BX.BE - news) by putting cash into shareholders’ hands sooner. Last month, Dublin-based Shire made an offer that valued Baxalta at $30.6bn, but it excluded cash. Shire said this was to maintain the tax-free status of Baxalta, which is a spinoff from Baxter International (NYSE: BAX - news) .
Help employers find you! Check out all the jobs and post your resume.
